H-1BSalary Explorer

Employers

Novo Nordisk Pharmaceutical Industries, LP H-1B salaries

Novo Nordisk Pharmaceutical Industries, LP filed 18 certified H-1B applications between Apr 2024 and Apr 2026. Half of them paid more than $128,637 a year.

Median salary offered
$128,637
Middle half earn
$110,767 to $134,864
Top 10% earn over
$145,604
Certified filings
18

Every filing

Loading filings…

Pay by job title

Job titleFilingsMedianMiddle half
QA Area Specialist IV2$132,250$131,146 – $133,353
Associate Manager, Quality Control Chemistry1$128,000$128,000 – $128,000
Facilities Engineer III - Clean Util API1$128,262$128,262 – $128,262
Principal Specialist - API1$162,706$162,706 – $162,706
Manager, Facilities Engineering - OFP1$152,000$152,000 – $152,000
Project Manager I - Product & Optimization Projects1$135,150$135,150 – $135,150
Project Manager II - Site Capacity1$129,012$129,012 – $129,012
Project Procurement Analyst1$88,528$88,528 – $88,528
Process Engineer III- Fermentation1$132,578$132,578 – $132,578
QA Area Specialist I - SDF1$80,340$80,340 – $80,340
Quality Control Analyst II OFP1$82,000$82,000 – $82,000
Sr Business Finance Advisor1$119,068$119,068 – $119,068
Strategic Business Partner1$142,863$142,863 – $142,863
Supply Chain Engineer1$135,000$135,000 – $135,000
Validation Area Specialist1$108,000$108,000 – $108,000
Validation Area Specialist III - Virginia1$125,000$125,000 – $125,000
Validation Area Specialist - Site Capacity1$108,000$108,000 – $108,000

Where they work

Bigger dots mean more filings; darker blue means higher pay.
CityFilingsMedianMiddle half
Clayton, NC12$131,310$116,301 – $135,038
Durham, NC4$105,000$81,585 – $134,000
Clayon, NC1$128,262$128,262 – $128,262
Petersburg, VA1$125,000$125,000 – $125,000

By year

Year filedFilingsMedian
20244$133,864
20259$125,000
20265$129,012

By experience level

Wage levelFilingsMedian
Level I1$80,340
Level II2$85,264
Level III3$108,000
Level IV12$133,518

Levels I to IV are the Labor Department's experience bands, from entry level (I) to fully competent (IV).